Evaluation of five antischizophrenic agents against toxoplasma gondii in human cell cultures

Journal of Parasitology

Volumn 97, Issue 1, 2011, Pages 148-151

  Goodwin, David G ^a   Strobl, Jeannine S ^a,b   Lindsay, David S ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; THIORIDAZINE; TRIFLUOPERAZINE; NEUROLEPTIC AGENT;

ANTIBODY; ASSAY; CELL ORGANELLE; DRUG; ENZYME ACTIVITY; INFECTIOUS DISEASE; INHIBITION; REMEDIATION; RODENT; STABILIZATION; TOXICITY;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IC 50; TACHYZOITE; TOXOPLASMA GONDII; CELL LINE; FIBROBLAST; GROWTH, DEVELOPMENT AND AGING; PARASITOLOGY; SCHIZOPHRENIA; TOXOPLASMA; TOXOPLASMOSIS;

RATTUS; TOXOPLASMA GONDII;

ANTIPSYCHOTIC AGENTS; CELL LINE; CLOZAPINE; FIBROBLASTS; FLUPHENAZINE; HALOPERIDOL; HUMANS; SCHIZOPHRENIA; THIORIDAZINE; TOXOPLASMA; TOXOPLASMOSIS; TRIFLUOPERAZINE;

EID: 79953829695     PISSN: 00223395     EISSN: 19372345     Source Type: Journal    
DOI: 10.1645/GE-2536.1     Document Type: Article

References (44)

1. ALVARADO-ESQUIVEL, C., O. P. ALANIS-QUIÑONES, M. Á. ARREOLAVALENZUELA, A. RODRÍGUEZ-BRIONES, L. J. PIEDRA-NEVAREZ, E. DURAN-MORALES, S. ESTRADA-MARTÍNEZ, S. A. MARTÍNEZ-GARCÍA, AND O. LIESENFELD. 2006. Seroepidemiology of Toxoplasma gondii infection in psychiatric inpatients in a northern Mexican city. BMC Infectious Diseases 6: 178.
2. BENNETT, T. N., M. PAGUIO, B.GLIGORIJEVIC, C. SEUDIEU, A. D.KOSAR, E. DAVIDSON, AND P. D. ROEPE. 2004. Novel, rapid, and inexpensive cellbased quantification of antimalarial drug efficacy. Antimicrobial Agents and Chemotherapy 48: 1807-1810. (Pubitemid 38544393)
3. BROWN, S. A., C. A. SCHAEFER, C. P. QUESENBERRY, JR., L. LIU, V. P. BABULAS, AND E. S. SUSSER. 2005. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. American Journal of Psychiatry 162: 767-773. (Pubitemid 40489141)
4. CARTER, C. J. 2009. Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: Cytomegalovirus, influenza, Herpes simplex, rubella, and Toxoplasma gondii. Schizophrenia Bulletin 35: 1163-1182.
5. CHANDRAMOHANADAS, R., P. H. DAVIS, D. P. BEITING, M. B. HARBUT, C. DARLING,G.VELMOUROUGANE,M.Y.LEE, P.A.GREER,D. S.ROOS, AND D.C.GREENBAUM. 2009. Apicomplexan parasites co-opt host calpains to facilitate their escape from infected cells. Science 324: 794-797.
6. CETINKAYA, Z., S. YAZAR, O. GECICI, AND M. N. NAMLI. 2007. Anti-Toxoplasma gondii antibodies in patients with schizophrenia-Preliminary findings in a Turkish sample. Schizophrenia Bulletin 33: 789-791. (Pubitemid 47343723)
7. CLEARY, M. F. 1977. Fluphenazine decanoate during pregnancy. American Journal of Psychology 134: 815-816. (Pubitemid 8137228)
8. DICKERSON, F. B., J. J. BORONOW, C. R. STALLINGS, A. E. ORIGONI, AND R. H. YOLKEN. 2007. Toxoplasma gondii in individuals with schizophrenia: Association with clinical and demographic factors and with mortality. Schizophrenia Bulletin 33: 737-740.
9. -, C. R. STALLINGS, J. J. BORONOW, A. E. ORIGONI, AND R. H. YOLKEN. 2009. A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. Schizophrenia Research 112: 198-199.
10. EINARSON, A., AND R. BOSKOVIC. 2009. Use and safety of antipsychotic drugs during pregnancy. Journal of Psychiatric Practice 15: 183-192.
11. GOLAN, D. E., A. H. TASHJIAN, JR., E. J. ARMSTRONG, AND A. W. ARMSTRONG. 2008. Principles of pharmacology. The pathophysiologic basis of drug therapy, 2nd ed. Lippincott, Williams & Williams, Philadelphia, Pennsylvania, 234 p.
12. GOODWIN, D. G., J. STROBL, S. M. MITCHELL, A. M. ZAJAC, AND D. S. LINDSAY. 2008. Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. Journal of Parasitology 94: 555-557. (Pubitemid 351706068)
13. HERM-GOTZ, A., S. WEISS, R. STRATMAN, S. FUJITA-BECKER, C. RUFF, E. MEYHOFER, T. SOLDATI, D. J. MANSTEIN, M. A. GEEVES, AND D. SOLDATI. 2002. Toxoplasma gondii myosin A and its light-chain: A fast, single-headed, plus-end-directed motor. The EMBO Journal 21: 2149-2158. (Pubitemid 34516774)
14. HOFF, E. F., AND V. B. CARRUTHERS. 2002. Is Toxoplasma egress the first step in invasion? Trends in Parasitology 18: 251-255. (Pubitemid 34569234)
15. JONES-BRANDO, L., E. F. TORREY, AND R. YOLKEN. 2003. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophrenia Research 62: 237-244. (Pubitemid 36775365)
16. KIRCHHERR, H., AND W. N. KUHN-VELTEN. 2006. Quantitative determination of forty-eight antidepressant and antipsychotics in human plasma by HPLC tandem mass spectrometry: A multi-level sample approach. Journal of Chromatography B 843: 100-113. (Pubitemid 44512257)
17. LOURIDO, S., J. SHUMAN, C. ZHANG, M. SHOKAT, R. HIU, AND L. D. SIBLEY. 2010. Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature 465: 359-362.
18. LOVETT, J. L., AND L. D. SIBLEY. 2003. Intracellular calcium stores in Toxoplasma gondii govern invasion of host cells. Journal of Cell Science 116: 3009-3016. (Pubitemid 36926989)
19. MIYAMOTO, S., G. E. DUNCAN, C. E. MARX, AND J. A. LIEBERMAN. 2005. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10: 79-104. (Pubitemid 40139590)
20. MORTENSEN, P. B., B. NøRGAARD-PEDERSEN, B. L. WALTOFT, T. L. SøRENSEN, D. HOUGAARD, AND R. H. YOLKEN. 2007. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophrenia Bulletin 33: 741-744. (Pubitemid 47343716)
21. -, -, -, -, -, E. F. TORREY, AND R. H. YOLKEN. 2007. Toxoplasma gondii as a risk factor for early-onset schizophrenia: Analysis of filter paper blood samples obtained at birth. Biological Psychiatry 61: 688-693. (Pubitemid 46328861)
22. MONTI, B., E. POLAZZI, AND A. CONTESTABILE. 2009. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Current Molecular Pharmacology 2: 95-109.
23. NAGAMUNE, K., L. M. HICKS, B. FUX, F. BROSSIER, E.N. CHINI, AND L. D. SIBLEY. 2008. Abscisic acid controls calcium-dependent egress and development in Toxoplasma gondii. Nature 45: 207-210.
24. NAKAZAWA, K., K. ITO, S. KOIZUMI, Y. OHNO, AND K. INOUE. 1995. Characterization of inhibition by haloperidol and chlorpromazine of a voltage-activated K+ current in rat phaeochromocytoma cells. British Journal of Pharmacology 116: 2603-2610.
25. NIEBUHR, D. W., A. M. MILLIKAN, D. N. COWAN, R. YOLKEN, Y. LI, AND N. S. WEBER. 2008. Selected infectious agents and risk of schizophrenia among U.S. military personnel. American Journal of Psychiatry 165: 99-106. (Pubitemid 351704558)
26. NINAN, I., K. E. JARDEMARK, X. LIANG, AND R. Y. WANG. 2003. Calciumcalmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA-and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse 47: 285-294. (Pubitemid 36160121)
27. PEZZELLA, N., A. BOUCHOT, A. BONHOMME, L. PINGRET, C. KLEIN, H. BURLET, G. BALOSSER, P. BONHOMME, AND J. M. PINON. 1997. Involvement of calcium and calmodulin in Toxoplasma gondii tachyzoite invasion. European Journal of Cell Biology 74: 92-101. (Pubitemid 27416899)
28. PEZZELLA-DALESSANDRO, N., H. LE MOAL, A. BONHOMME, A. VALERO, C. KLEIN, J. GOMEZ-MORINO, AND J. M. PINON. 2001. Calmodulin distribution and the actomyosin cytoskeleton in Toxoplasma gondii. Journal of Histochemistry and Cytochemistry 49: 445-454.
29. PROZIALECK, W. C., AND B. WEISS. 1982. Inhibition of calmodulin by phenothiazines and related drugs: Structure activity relationships. Journal of Pharmacology and Experimental Therapeutics 222: 509-516. (Pubitemid 12018819)
30. QIN, J., A. V. ZIMA, M. PORTA, L. A. BLATTER, AND M. FILL. 2009. Trifluoperazine a ryanodine receptor agaonist. Pflügers Archiv-European Journal of Physiology 458: 643-651.
31. REGIER, D. A., W. E. NARROW, D. S. RAE, R. W. MANDERSCHEID, B. Z. LOCKE, AND E. K. GOODWIN. 1993. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry 50: 85-94. (Pubitemid 23059313)
32. SABIN, A. B. 1941. Toxoplasmic encephalitis in children. Journal of the American Medical Association 116: 801-807.
33. SHIBRE, T., A. ALEM, A.ABDULAHI, M. ARAYA, T. BEYERO, G.MEDHIN, N. DEYASSA, A. NEGASH, A. NIGATU, D. KEBEDE, AND A. FEKADU. 2010. Trimethoprim as adjuvant treatment in schizophrenia: A doubleblind, randomized, placebo-controlled clinical trial. Schizophrenia Bulletin 36: 846-851.
34. SHIN, S. Y., B. H. CHOI, J.KO, S.H.KIM, Y. S.KIM, AND Y. H. LEE. 2006. Clozapine, a neuroleptic agent, inhibits Akt by counteracting Ca+2/ calmodulin in PTEN-negative U087MG human glioma cells. Cell Signaling 18: 1876-1886. (Pubitemid 44485978)
35. STROBL, J. S., M. CASSELL, S. M. MITCHELL, C. M. REILLY, AND D. S. LINDSAY. 2007. Scriptaid and suberoylanilidehydroxamic acid are histonedeacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. Journal of Parasitology 93: 694-700. (Pubitemid 47036095)
36. -, C. W. SEIBERT, Y. LI, R. NAGARKATTI, S. M. MITCHELL, A. C. ROSYPAL, D. RATHORE, AND D. S. LINDSAY. 2009. Inhibition of Toxoplasma gondii and Plasmodium falciparum infections in vitro by NSC3852, a redox active antiproliferative and tumor cell differentiation agent. Journal of Parasitology 95: 215-223.
37. SUESSBRICH, H., R. SCHONHERR, S. H. HEINEMANN, B. ATTALI, F. LANG, AND A. E. BUSCH. 1997. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. British Journal of Pharmacology 120: 968-974. (Pubitemid 27122740)
38. TANG, L., R. D. TODD, A. HELLER, AND K. L. OMALLEY. 1994. Pharmacological and functional characterization of D2, D2 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. Journal of Pharmacology and Experimental Therapeutics. 268: 495-502. (Pubitemid 24039127)
39. VAID, A., D. C. THOMAS, AND P. SHARMA. 2008. Role of Ca+2/calmodulin- PfPKB signaling pathway in erythrocyte invasion by Plasmodium falciparum. Journal of Biological Chemistry 283: 5589-5597.
40. WAGNER, R., R. H. FINK, AND D. G. STEPHENSON. 2004. Effects of chlorpromazine on excitation-coupling events in fast-twitch skeletal muscle fibers of the rat. British Journal of Pharmacology 141: 624-633. (Pubitemid 38453254)
41. WANG, H. L., G. H. WANG, Q. Y. LI, C. SHU, M. S. JIANG, AND Y. GUO. 2006. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatria Scandanavia 114: 40-48. (Pubitemid 43885484)
42. WEBSTER, J. P., P. H. LAMBERTON, C. A. DONNELLY, AND E. F. TORREY. 2006. Parasites as causative agents of human affective disorders? The impact of antipsychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondiis ability to alter host behaviour. Proceedings of the Royal Society B: Biological Science 273: 1023-1030. (Pubitemid 46768431)
43. WURTZ, N., J. DESPLANS, AND D. PARZY. 2009. Phenotypic and transcriptomic analysis of Plasmodium falciparum protein kinase A catalytic subunit inhibition. Parasitology Research 105: 1691-1699.
44. YARIS, F., E. YARIS, M. KADIOGLU, C. ULKU, M. KESIM, AND N. I. KALYONCU. 2004. Use of polypharmacotherapy in pregnancy: A prospective outcome in a case. Progress in Neuropsychopharmacology and Biological Psychiatry 28: 603-605. (Pubitemid 38490774)